Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CagriSema in Participants With Type 2 Diabetes Inadequately Controlled on Metformin
NCT06065540Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Primary completion
- Nov 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial of cagrilintide and semaglutide in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Novo Nordisk. Primary endpoint: Change in glycated haemoglobin (HbA1c) at 68 weeks. Started Sep 2023; status: completed.
02
Drugs
cagrilintidesemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06065540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065540.